copolymer-1

copolymer-1

acetate salt of a mixture of synthetic polypeptides composed of four amino acids; used to reduce the relapse rate with relapsing-remitting multiple sclerosis.
Farlex Partner Medical Dictionary © Farlex 2012

co·pol·y·mer-1

(kō'pol'i-mĕr)
Acetate salt of a mixture of synthetic polypeptides composed of four amino acids; used to reduce the relapse rate with relapsing-remitting multiple sclerosis.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

copolymer-1

A mixture of synthetic random polypeptides made from the amino acids alanine, glutamic acid, lysine and tyrosine that has been found to reduce the relapse rate in MULTIPLE SCLEROSIS. Research suggests that the drug can reduce the relapse rate, in patients subject to relapses, from 75 per cent to 66 per cent. The drug is believed to act on helper T cells so as to promote cloning of those whose CYTOKINES are mainly B cell antibody-stimulating (Th-2) rather than those whose cytokines have a mainly inflammatory and destructive effect (Th-1). A brand name is Copaxone.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
This article reviews the results of the rigorously-controlled clinical trial focusing on the use of copolymer-1 in the treatment of patients with relapsing-remitting MS.
Copolymer-1 (Copaxone[R]), is an acetate salt resulting from a mixture of synthetic polypeptides composed of the four amino acids L-alanine L-glutamic acid, L-lysine and L-tyrosine.
Copolymer-1 was first synthesized in 1967, and was studied extensively in animal models.
Copolymer-1 was studied by Johnson et al in 1995, in a multicenter, phase III trial of patients with relapsing-remitting multiple sclerosis.[5] The two-year study included 251 randomized patients who received copolymer-1 (n= 125) or placebo (n = 126).
Patients who had been treated with copolymer-1 or any other immuno-suppressive therapy, chemotherapy or lymphoid irradiation were also excluded.[5]
A transient, self-limiting systemic reaction followed the injection in 15.2% of those receiving copolymer-1 and 3.2% in those receiving placebo.
The results showed a final two-year relapse rate of 1.19 [+ or -] 0.13 for patients receiving copolymer-1 and 1.68 [+ or -] 0.13 for patients receiving placebo.
Nurses are in a unique position to give patients taking copolymer-1 advice about medication administration and storage, adverse effects, psychological/psychosocial issues, as well as tips for proper administration.
The only recommended route of administration for injection of copolymer-1 is the subcutaneous route, and care should be taken to avoid inadvertent intravenous (IV) or intramuscular (IM) administration.
Reconstitution of copolymer-1 is done by carefully injecting the diluent down the inside wall of the vial, avoiding injection directly on the cake of medication.
Patients should be advised about the common adverse effects associated with administration of copolymer-1. Injection site reaction is the most common adverse effect.
Also, patients should be advised to self-administer copolymer-1 at a time of day they feel strongest, and when a significant other can be present to observe for possible adverse reactions.